Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroblastoma 1Nerve Sheath Neoplasms 1Neoplasm Metastasis 1Myoepithelioma 1Giant Cell Tumor of Bone 1Desmoplastic Small Round Cell Tumor 1Clear-cell metastatic renal cell carcinoma 1Chordoma 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Zoledronic Acid × 90 days × Clear all
NCT07043608 2026-05-01

ZAMBONI

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03295981 2026-04-22

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

St. Louis University

Phase 3 Recruiting
120 enrolled

Giant Cell Tumor of Bone

NCT06374459 2026-04-20

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Washington University School of Medicine

Phase 1/2 Recruiting
152 enrolled
Breast

Breast Neoplasms

NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT06625190 2026-03-11

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

University of Florida

Phase 1/2 Recruiting
27 enrolled
CNSSarcoma

Chordoma, Myoepithelioma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡